Muriel Jean-Jacques, MD, MAPP

home / authors / muriel-jean-jacques-md-mapp

Articles

August 23rd 2016

The Longitudinal Impact of Aligning Forces for Quality on Measures of Population Health, Quality and Experience of Care, and Cost of Care

Yunfeng Shi, PhD Dennis P. Scanlon, PhD Raymond Kang, MA Megan McHugh, PhD Jessica Greene, PhD Jon B. Christianson, PhD Muriel Jean-Jacques, MD, MAPP Yasmin Mahmud, MPH Jeffrey A. Alexande

August 23rd 2016

Evaluating a Complex, Multi-Site, Community-Based Program to Improve Healthcare Quality: The Summative Research Design for the Aligning Forces for Quality Initiative

Dennis P. Scanlon, PhD Laura J. Wolf, MSW Jeffrey A. Alexander, PhD Jon B. Christianson, PhD Jessica Greene, PhD Muriel Jean-Jacques, MD, MAPP Megan McHugh, PhD Yunfeng Shi, PhD Brigitt Leitze

August 23rd 2016

Summative Evaluation Results and Lessons Learned From the Aligning Forces for Quality Program

Dennis P. Scanlon, PhD Jeffrey A. Alexander, PhD Megan McHugh, PhD Jeff Beich, PhD Jon B. Christianson, PhD Jessica Greene, PhD Muriel Jean-Jacques, MD, MAPP Brigitt Leitzell, MS Yunfeng Shi,

August 23rd 2016

Lessons Learned About Advancing Healthcare Equity From the Aligning Forces for Quality Initiative

Muriel Jean-Jacques, MD, MAPP Yasmin Mahmud, MPH Jaime Hamil, MPH Raymond Kang, MA Philethea Duckett, MPA Juliet C. Yonek, MPH, PhD

Latest Updated Articles

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

AJMC Q&A with Dr Kristen Whitney | Background image credit: ipopba - stock.adobe.com

Published: August 28th 2024 | Updated: September 8th 2024

Illuminating the Future: Dr Kristen Whitney on What's Next for Dermoscopy

LDL and Lp(a) | Image credit : Amgen

Published: August 4th 2024 | Updated: September 8th 2024

Who Should Have Lp(a) Levels Tested? Experts Take Sides

ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

Published: September 3rd 2024 | Updated: September 8th 2024

ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

Published: September 3rd 2024 | Updated: September 8th 2024

Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

Psoriasis | image credit: pimentos – stock.adobe.com.jpg

Published: August 28th 2024 | Updated: September 8th 2024

TYK2 Inhibitor Zasocitinib Shows High Efficacy, Safety in Moderate to Severe Psoriasis

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions